# Verdict: anti_yo_cerebellar_degeneration.md (re-verification after rewrite)

1. DOSE LEAK: none. No mg / mg-m2 / AUC / numbered schedule anywhere, despite DeVita's
   actual ch.89 treatment paragraph carrying extensive dosing (methylprednisolone 1 g/day
   x3-5d, prednisone 1-1.25 g/day, IVIG 0.4-2 mg/kg x5d, plasma exchange q.o.d. x5-7,
   rituximab 375 mg/m2 weekly x4, azathioprine 2-3 mg/kg/day, mycophenolate 500-1000 mg
   BID, cyclophosphamide 1000 mg/m2 IV monthly or 1-2 mg/kg/day PO, tocilizumab
   8 mg/kg monthly). All correctly stripped to drug-name-only. Only other numeric in the
   file is "70 percent" (high-risk antibody threshold, a probability category, not a dose)
   and "12th ed." — neither is a dose leak.

2. UNGROUNDED / MISLABELLED CLAIMS: the one defect flagged in the prior adversarial pass
   (CDR2/CDR2L antigen identity stated inline as though DeVita's chapter names it) is
   fixed. Line 11 now reads "(CDR2/CDR2L - general immunology knowledge, not stated in
   DeVita's PNS chapter)", and the adjacent genuinely-sourced claim (intracellular vs.
   surface-antigen antibodies respond worse to immunotherapy) is now split into its own
   sentence ("the same chapter separately notes...") rather than being bundled under one
   ambiguous "the same chapter notes" umbrella. Re-checked ch.89 (devita.txt ~323100-323480):
   Purkinje cells / CDR2 / CDR2L are never named in the chapter and Table 89.1 has no
   antigen-locality column, so the relabel is correct and now attaches to the right clause.
   Spot-checked everything else again directly against the source text:
   - Yo (PCA-1) -> RPCS -> ovary/breast cancer, high-risk (>70%) category — matches
     Table 89.1.
   - "should not wait for autoantibody results... once viral/bacterial infection
     excluded" — verbatim match.
   - First-line = corticosteroid, then IVIG/plasma exchange; second-line =
     rituximab/azathioprine/mycophenolate/cyclophosphamide; tocilizumab tied to
     rituximab-refractory autoimmune encephalitis and bortezomib to NMDAR encephalitis
     specifically, both correctly flagged as not established for Yo — matches source,
     no invented attribution.
   - "In addition to addressing the primary tumor... treatment is based on
     immunotherapeutic approaches" — verbatim-sourced parallel-priority framing.
   - Every claim beyond DeVita (Purkinje-loss plateau, platinum/anthracycline-class
     systemic therapy for the primary, risk-reducing surgery, monitoring cadence, rehab
     referral, genetic counseling/BRCA scoped out) carries the
     "(general oncology standard, not from DeVita's section on this disease...)"
     disclaimer or an equivalent explicit non-DeVita phrase. No mis-attribution found.

3. CITATION: "Sources: DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of
   Oncology, 12th ed." — name + edition only, no page numbers. Present at end of file.

4. VERDICT: CLEAN — ready for R1 re-review. The prior blocking defect is resolved; no new
   fabrication, dose leak, or mislabelling introduced by the rewrite.
